Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study
Open Access
- 1 March 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 28 (3), 704-712
- https://doi.org/10.1093/carcin/bgl200
Abstract
Recent findings suggest that genetic polymorphisms in TNF and IL10 are associated with an increased risk of non-Hodgkin lymphoma (NHL), particularly for diffuse large B-cell lymphoma (DLBCL). To further investigate the contribution of common genetic variation in key cytokine and innate immunity genes to the etiology of NHL, we genotyped participants in a case–control study of NHL conducted in Australia (545 cases, 498 controls). We investigated 36 single nucleotide polymorphisms in IL10, TNF and 21 other immune function genes. We observed an elevated risk of DLBCL with the IL10 −3575T>A polymorphism [TA genotype: odds ratio (OR) = 1.32, 95% confidence interval (CI) = 0.86–2.02; AA, OR = 1.84, 95% CI = 1.10–3.08; trend test, P = 0.02]. Our most noteworthy TNF finding was an association between −857C>T and a decreased risk of NHL (CT or TT, OR = 0.59, 95% CI = 0.42–0.84, P = 0.003) and particularly follicular lymphoma (OR = 0.40, 95% CI = 0.23–0.68, P = 0.0009). Additionally, TNF −863C>A was associated with an elevated risk of DLBCL (CA, OR = 1.45, 95% CI = 0.95–2.21; AA, OR = 2.06, 95% CI = 0.88–4.83; trend test, P = 0.02). Our findings offer further evidence that variation in the IL10 and TNF loci influences NHL risk. Additional studies are needed to clarify the genetic and biologic basis for these relationships.Keywords
This publication has 46 references indexed in Scilit:
- B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDSAIDS, 2000
- High Serum Interleukin-6 Levels Correlate with a Shorter Failure-Free Survival in Indolent LymphomaLeukemia & Lymphoma, 1998
- Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.Journal of Clinical Oncology, 1997
- Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphomaEuropean Journal of Haematology, 1996
- ELEVATED CIRCULATING LEVELS OF TNFα AND ITS p55 SOLUBLE RECEPTOR ARE ASSOCIATED WITH AN ADVERSE PROGNOSIS IN LYMPHOMA PATIENTSBritish Journal of Haematology, 1996
- Clinical Significance of Serial Measurement of the Serum Levels of Soluble Interleukin-2 Receptor and Soluble CD8 in Malignant LymphomaLeukemia & Lymphoma, 1995
- Prognostic value of serum IL‐10 and soluble IL‐2 receptor levels in aggressive non‐Hodgkin's lymphomaBritish Journal of Haematology, 1994
- Increased levels of circulating interleukin-6 in patients with newly diagnosed non-Hodgkin's lymphomasAmerican Journal of Hematology, 1994
- Prognosis in low grade non‐Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin levelHematological Oncology, 1994
- Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.Journal of Clinical Oncology, 1993